Molecular tuning of farnesoid X receptor partial agonism.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
02 07 2019
Historique:
received: 18 10 2018
accepted: 31 05 2019
entrez: 4 7 2019
pubmed: 4 7 2019
medline: 10 9 2019
Statut: epublish

Résumé

The bile acid-sensing transcription factor farnesoid X receptor (FXR) regulates multiple metabolic processes. Modulation of FXR is desired to overcome several metabolic pathologies but pharmacological administration of full FXR agonists has been plagued by mechanism-based side effects. We have developed a modulator that partially activates FXR in vitro and in mice. Here we report the elucidation of the molecular mechanism that drives partial FXR activation by crystallography- and NMR-based structural biology. Natural and synthetic FXR agonists stabilize formation of an extended helix α11 and the α11-α12 loop upon binding. This strengthens a network of hydrogen bonds, repositions helix α12 and enables co-activator recruitment. Partial agonism in contrast is conferred by a kink in helix α11 that destabilizes the α11-α12 loop, a critical determinant for helix α12 orientation. Thereby, the synthetic partial agonist induces conformational states, capable of recruiting both co-repressors and co-activators leading to an equilibrium of co-activator and co-repressor binding.

Identifiants

pubmed: 31266946
doi: 10.1038/s41467-019-10853-2
pii: 10.1038/s41467-019-10853-2
pmc: PMC6606567
doi:

Substances chimiques

Co-Repressor Proteins 0
Ligands 0
Receptors, Cytoplasmic and Nuclear 0
farnesoid X-activated receptor 0C5V0MRU6P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2915

Références

J Med Chem. 2015 Dec 24;58(24):9768-72
pubmed: 26568144
Bioorg Med Chem. 2014 Apr 15;22(8):2447-60
pubmed: 24685112
Planta Med. 2006 Aug;72(10):881-7
pubmed: 16858665
Curr Top Med Chem. 2014;14(19):2188-205
pubmed: 25388533
Sci Rep. 2015 Dec 01;5:17288
pubmed: 26620317
J Biol Chem. 2001 Aug 3;276(31):28857-65
pubmed: 11387316
Science. 1999 May 21;284(5418):1365-8
pubmed: 10334993
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Nat Med. 2015 Feb;21(2):159-65
pubmed: 25559344
Bioorg Med Chem. 2015 Feb 1;23(3):499-514
pubmed: 25583100
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5337-42
pubmed: 18391212
J Pharmacol Sci. 2005 Dec;99(4):342-52
pubmed: 16314690
J Synchrotron Radiat. 2012 May;19(Pt 3):442-9
pubmed: 22514183
J Med Chem. 2017 Jul 13;60(13):5235-5266
pubmed: 28252961
Trends Biochem Sci. 2015 Jan;40(1):16-24
pubmed: 25435400
Bioorg Med Chem Lett. 2008 Aug 1;18(15):4339-43
pubmed: 18621523
J Med Chem. 2000 Aug 10;43(16):2971-4
pubmed: 10956205
Science. 1999 May 21;284(5418):1362-5
pubmed: 10334992
Biochem Pharmacol. 2012 Jun 15;83(12):1674-81
pubmed: 22414727
J Med Chem. 2019 Feb 28;62(4):2112-2126
pubmed: 30702885
Trends Biochem Sci. 2015 Jan;40(1):25-35
pubmed: 25499868
Bioorg Med Chem. 2015 Jul 1;23(13):3490-8
pubmed: 25934227
J Biol Chem. 2003 Mar 21;278(12):10214-20
pubmed: 12525500
J Med Chem. 2014 Oct 9;57(19):8035-55
pubmed: 25255039
Nature. 1995 Dec 14;378(6558):681-9
pubmed: 7501014
Biochim Biophys Acta. 2007 Jul;1771(7):864-72
pubmed: 17500032
Future Med Chem. 2016;8(2):133-48
pubmed: 26824277
Physiol Rev. 2001 Jul;81(3):1269-304
pubmed: 11427696
Nat Commun. 2013;4:1937
pubmed: 23728580
J Med Chem. 2002 Aug 15;45(17):3569-72
pubmed: 12166927
J Comput Aided Mol Des. 2018 Jan;32(1):1-20
pubmed: 29204945
Chembiochem. 2017 Apr 18;18(8):721-725
pubmed: 28186695
Mol Cell. 2003 Apr;11(4):1079-92
pubmed: 12718892
J Med Chem. 2017 Aug 24;60(16):7199-7205
pubmed: 28749691
Dig Dis. 2015;33(3):327-31
pubmed: 26045265
Gastroenterology. 2015 Apr;148(4):751-61.e8
pubmed: 25500425
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Sci Rep. 2018 May 1;8(1):6846
pubmed: 29717168
Drug Discov Today. 2012 Sep;17(17-18):988-97
pubmed: 22652341
Gastroenterology. 2013 Sep;145(3):574-82.e1
pubmed: 23727264
Mol Cell. 2003 Apr;11(4):1093-100
pubmed: 12718893
Sci Rep. 2018 Sep 10;8(1):13554
pubmed: 30202096
Lancet. 2015 Mar 14;385(9972):956-65
pubmed: 25468160

Auteurs

Daniel Merk (D)

Institute of Pharmaceutical Chemistry, Goethe University, Frankfurt, 60348, Germany. merk@pharmchem.uni-frankfurt.de.

Sridhar Sreeramulu (S)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany.

Denis Kudlinzki (D)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany.
German Cancer Consortium (DKTK), Heidelberg, 69120, Germany.
German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.

Krishna Saxena (K)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany.
German Cancer Consortium (DKTK), Heidelberg, 69120, Germany.
German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.

Verena Linhard (V)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany.

Santosh L Gande (SL)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany.
German Cancer Consortium (DKTK), Heidelberg, 69120, Germany.
German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.

Fabian Hiller (F)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany.

Christina Lamers (C)

Institute of Pharmaceutical Chemistry, Goethe University, Frankfurt, 60348, Germany.

Ewa Nilsson (E)

Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, 43183, Sweden.

Anna Aagaard (A)

Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, 43183, Sweden.

Lisa Wissler (L)

Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, 43183, Sweden.

Niek Dekker (N)

Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, 43183, Sweden.

Krister Bamberg (K)

Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, 43183, Sweden.

Manfred Schubert-Zsilavecz (M)

Institute of Pharmaceutical Chemistry, Goethe University, Frankfurt, 60348, Germany.

Harald Schwalbe (H)

Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Goethe University, Frankfurt, 60438, Germany. schwalbe@em.uni-frankfurt.de.
German Cancer Consortium (DKTK), Heidelberg, 69120, Germany. schwalbe@em.uni-frankfurt.de.
German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany. schwalbe@em.uni-frankfurt.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH